Massimo Galli

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1862755/massimo-galli-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

298 papers	10,187 citations	48 h-index	92 g-index
312 ext. papers	12,386 ext. citations	6 avg, IF	6.31 L-index

#	Paper	IF	Citations
298	Mortality among Italians and immigrants with COVID-19 hospitalised in Milan, Italy: data from the Luigi Sacco Hospital registry.. *BMC Infectious Diseases*, **2022**, 22, 63	4	1
297	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy.. *Lancet Infectious Diseases, The*, **2022**,	25.5	1
296	Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICOVID19 Study.. *International Journal of Environmental Research and Public Health*, **2022**, 19,	4.6	2
295	Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study.. *BMC Medicine*, **2022**, 20, 52	11.4	0
294	The value of lamp to rule out imported malaria diagnosis: a retrospective observational study in Milan, Italy.. *Infectious Diseases*, **2022**, 1-8	3.1	
293	Influenza Vaccination Uptake in the General Italian Population during the 2020-2021 Flu Season: Data from the EPICOVID-19 Online Web-Based Survey.. *Vaccines*, **2022**, 10,	5.3	2
292	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020.. *Scientific Reports*, **2022**, 12, 5736	4.9	1
291	PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. *JCI Insight*, **2021**,	9.9	7
290	Stratification of the risk of developing severe or lethal Covid-19 using a new score from a large Italian population: a population-based cohort study. *BMJ Open*, **2021**, 11, e053281	3	2
289	Accessibility to SARS-CoV-2 swab test during the Covid-19 pandemic: Did age make the difference?. *Health Policy*, **2021**, 125, 1580-1586	3.2	1
288	Chest X-ray findings in a large cohort of 1117 patients with SARS-CoV-2 infection: a multicenter study during COVID-19 outbreak in Italy. *Internal and Emergency Medicine*, **2021**, 16, 1173-1181	3.7	5
287	Prevalence and outcome of silent hypoxemia in COVID-19. *Minerva Anestesiologica*, **2021**, 87, 325-333	1.9	22
286	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. *Cell*, **2021**, 184, 1171-1187.e20	56.2	331
285	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. *Digestive and Liver Disease*, **2021**,	3.3	4
284	Anti-Tat immunity defines CD4 T-cell dynamics in people living with HIV on long-term cART. *EBioMedicine*, **2021**, 66, 103306	8.8	3
283	Association Between Smoking and SARS-CoV-2 Infection: Cross-sectional Study of the EPICOVID19 Internet-Based Survey. *JMIR Public Health and Surveillance*, **2021**, 7, e27091	11.4	9
282	Age-Related Changes in Clinical Presentation of Covid-19: the EPICOVID19 Web-Based Survey. *European Journal of Internal Medicine*, **2021**, 86, 41-47	3.9	10

281	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. *Frontiers in Immunology*, **2021**, 12, 656362	8.4	18
280	Are Epidemiological Estimates Able to Describe the Ability of Health Systems to Cope with COVID-19 Epidemic?. *Risk Management and Healthcare Policy*, **2021**, 14, 2221-2229	2.8	2
279	Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. *Nature Metabolism*, **2021**, 3, 774-785	14.6	78
278	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). *Viruses*, **2021**, 13,	6.2	4
277	SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response. *Journal of Medical Virology*, **2021**, 93, 6444-6446	19.7	5
276	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). *Internal and Emergency Medicine*, **2021**, 16, 149-156	3.7	7
275	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. *Journal of Medical Virology*, **2021**, 93, 1421-1427	19.7	17
274	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. *Journal of Autoimmunity*, **2021**, 116, 102545	15.5	18
273	Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience. *International Journal of Cardiology*, **2021**, 323, 276-280	3.2	26
272	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. *Multiple Sclerosis Journal*, **2021**, 27, 347-359	5	24
271	Rapid COVID-19 Screening Based on Self-Reported Symptoms: Psychometric Assessment and Validation of the EPICOVID19 Short Diagnostic Scale. *Journal of Medical Internet Research*, **2021**, 23, e23897	7.6	15
270	Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. *Journal of Clinical Lipidology*, **2021**, 15, 68-78	4.9	24
269	Human-to-Cat SARS-CoV-2 Transmission: Case Report and Full-Genome Sequencing from an Infected Pet and Its Owner in Northern Italy. *Pathogens*, **2021**, 10,	4.5	19
268	Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy. *PLoS ONE*, **2021**, 16, e0246513	3.7	7
267	Consumption of antibiotics at an Italian university hospital during the early months of the COVID-19 pandemic: Were all antibiotic prescriptions appropriate?. *Pharmacological Research*, **2021** , 164, 105403	10.2	7
266	Detecting HCV infection by means of mass population SARS-CoV-2 screening: A pilot experience in Northern Italy. *Journal of Hepatology*, **2021**, 75, 484-486	13.4	8
265	Retinal vessels modifications in acute and post-COVID-19. *Scientific Reports*, **2021**, 11, 19373	4.9	7
264	Predicting Severe/Critical Outcomes in Patients With SARS-CoV2 Pneumonia: Development of the prediCtion seveRe/crItical ouTcome in COVID-19 (CRITIC) Model. *Frontiers in Medicine*, **2021**, 8, 695195	4.9	0

263	The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 130, 72-77	2.2	3
262	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. *Clinical and Experimental Rheumatology*, **2021**, 39, 695	2.2	
261	Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 129, 149-154	2.2	1
260	Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. *Clinical and Experimental Rheumatology*, **2021**, 39, 149-154	2.2	1
259	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. *Autoimmunity Reviews*, **2020**, 19, 102574	13.6	29
258	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. *Pharmacological Research*, **2020**, 158, 104899	10.2	118
257	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *New England Journal of Medicine*, **2020**, 383, 1827-1837	59.2	778
256	Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. *Radiologia Medica*, **2020**, 125, 636-646	6.5	88
255	Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. *Journal of Clinical Medicine*, **2020**, 9,	5.1	47
254	Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. *Acta Diabetologica*, **2020**, 57, 779-783	3.9	98
253	Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet Infectious Diseases, The*, **2020**, 20, 1135-1140	25.5	742
252	Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. *Clinical Infectious Diseases*, **2020**, 71, 889-890	11.6	754
251	Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy. *Journal of Medical Virology*, **2020**, 92, 1637-1640	19.7	90
250	SARS-COV-2 infection: Across the border into the family. *Travel Medicine and Infectious Disease*, **2020**, 36, 101784	8.4	4
249	Early phylogenetic estimate of the effective reproduction number of SARS-CoV-2. *Journal of Medical Virology*, **2020**, 92, 675-679	19.7	106
248	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. *Liver International*, **2020**, 40, 1545-1555	7.9	19
247	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. *PLoS ONE*, **2020**, 15, e0242278	3.7	5
246	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOVID19 Web-Based Survey. *JMIR Public Health and Surveillance*, **2020**, 6, e21866	11.4	38

245	Heterogeneity of COVID-19 outbreak in Italy. *Acta Biomedica*, **2020**, 91, 31-34	3.2	15
244	30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacological Research*, **2020**, 158, 104931	10.2	140
243	Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. *International Journal of Infectious Diseases*, **2020**, 92, 62-68	10.5	6
242	Contribution of transgender sex workers to the complexity of the HIV-1 epidemic in the metropolitan area of Milan. *Sexually Transmitted Infections*, **2020**, 96, 451-456	2.8	3
241	Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. *EClinicalMedicine*, **2020**, 27, 100550	11.3	102
240	Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. *Diabetes Care*, **2020**, 43, 2999-3006	14.6	133
239	The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. *Medicine (United States)*, **2020**, 99, e22433	1.8	12
238	Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey. *Vaccines*, **2020**, 8,	5.3	5
237	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. *Viruses*, **2020**, 12,	6.2	30
236	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science*, **2020**, 370, 950-957	33.3	314
235	Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. *Journal of Infection*, **2020**, 81, e10-e12	18.9	44
234	The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey. *Vaccines*, **2020**, 8,	5.3	37
233	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. *World Journal of Biological Psychiatry*, **2020**, 21, 651-657	3.8	6
232	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. *Clinical and Experimental Rheumatology*, **2020**, 38, 245-256	2.2	1
231	COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. *Clinical and Experimental Rheumatology*, **2020**, 38, 337-342	2.2	218
230	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? **2020**, 15, e0242278		
229	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? **2020**, 15, e0242278		
228	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? **2020**, 15, e0242278		

227	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? **2020**, 15, e0242278		
226	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? **2020**, 15, e0242278		
225	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? **2020**, 15, e0242278		
224	Evolutionary Dynamics of the Lineage 2 West Nile Virus That Caused the Largest European Epidemic: Italy 2011-2018. *Viruses*, **2019**, 11,	6.2	19
223	Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. *Autoimmunity Reviews*, **2019**, 18, 778-785	13.6	15
222	Drug-induced liver steatosis in patients with HIV infection. *Pharmacological Research*, **2019**, 145, 104267	10.2	2
221	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. *Frontiers in Microbiology*, **2019**, 10, 769	5.7	3
220	Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects. *Drug Design, Development and Therapy*, **2019**, 13, 2271-2282	4.4	5
219	Chagas disease in Italy: the study's contribution of Italian researchers. *Panminerva Medica*, **2019**, 61, 464-472	2	2
218	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. *Frontiers in Immunology*, **2019**, 10, 233	8.4	12
217	Lung ultrasound in the management of pneumocystis pneumonia: A case series. *International Journal of STD and AIDS*, **2019**, 30, 188-193	1.4	5
216	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2018**, 77, 86-92	3.1	19
215	Epidemiological and clinical characteristics of imported malaria in adults in Milan, Italy, 2010-2015. *European Journal of Internal Medicine*, **2018**, 57, e13-e16	3.9	3
214	Epidemiological trends of infective endocarditis in a single center in Italy between 2003-2015. *Infectious Diseases*, **2018**, 50, 749-756	3.1	9
213	Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience. *European Journal of Gastroenterology and Hepatology*, **2018**, 30, 1208-1215	2.2	12
212	Origin and evolutionary dynamics of Hepatitis B virus (HBV) genotype E in Madagascar. *Pathogens and Global Health*, **2017**, 111, 23-30	3.1	0
211	Chagas disease in Europe: A review for the internist in the globalized world. *European Journal of Internal Medicine*, **2017**, 43, 6-15	3.9	99
210	Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 75, 315-321	3.1	9

209	Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. *Drug Metabolism and Personalized Therapy*, **2017**, 32, 115-117	2	
208	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. *Joint Bone Spine*, **2017**, 84, 525-530	2.9	12
207	Severe Plasmodium falciparum malaria in the intensive care unit: A 6-year experience in Milano, Italy. *Travel Medicine and Infectious Disease*, **2017**, 17, 43-49	8.4	9
206	Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 2879-2886	5.1	23
205	Is imported onchocerciasis a truly rare entity? Case report and review of the literature. *Travel Medicine and Infectious Disease*, **2017**, 16, 11-17	8.4	8
204	Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication. *American Journal of Gastroenterology*, **2017**, 112, 1753-1754	0.7	6
203	Critically ill patients at risk of invasive candidiasis: The "dilemma" of the best antifungal treatment strategy. *European Journal of Internal Medicine*, **2017**, 37, e20-e21	3.9	1
202	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. *PLoS ONE*, **2017**, 12, e0171611	3.7	9
201	Reconstructing the recent West Nile virus lineage 2 epidemic in Europe and Italy using discrete and continuous phylogeography. *PLoS ONE*, **2017**, 12, e0179679	3.7	32
200	HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 103, 67-76	2.2	8
199	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. *Clinical and Experimental Rheumatology*, **2017**, 35, 1018-1028	2.2	7
198	Diffusion and transmission of carbapenem-resistant Klebsiella pneumoniae in the medical and surgical wards of a university hospital in Milan, Italy. *Journal of Infection and Public Health*, **2016**, 9, 24-33	7.4	11
197	Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?. *Antiviral Therapy*, **2016**, 21, 529-534	1.6	4
196	Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. *Rheumatology*, **2016**, 55, 2084-2085	3.9	53
195	Distribution of Marburg virus in Africa: An evolutionary approach. *Infection, Genetics and Evolution*, **2016**, 44, 8-16	4.5	2
194	Dating the origin and dispersal of Human Papillomavirus type 16 on the basis of ancestral human migrations. *Infection, Genetics and Evolution*, **2016**, 39, 258-264	4.5	2
193	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. *PLoS ONE*, **2016**, 11, e0160761	3.7	4
192	HBV Virus in the Future **2016**, 31-64		

191	Candidemia and invasive candidiasis in adults: A narrative review. *European Journal of Internal Medicine*, **2016**, 34, 21-28	3.9	114
190	Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients. *Antiviral Research*, **2016**, 129, 52-57	10.8	2
189	When food can make the difference: The case of elvitegravir-based co-formulation. *International Journal of Pharmaceutics*, **2016**, 512, 301-304	6.5	7
188	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. *New Microbiologica*, **2016**, 39, 93-109	1.1	13
187	Hepatitis B virus genotype and subgenotype prevalence and distribution in Montenegro. *Journal of Medical Virology*, **2015**, 87, 807-13	19.7	4
186	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. *Journal of Autoimmunity*, **2015**, 63, 88-93	15.5	30
185	High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy. *Clinical Infectious Diseases*, **2015**, 60, 1873-5	11.6	17
184	Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. *Therapeutic Drug Monitoring*, **2015**, 37, 119-25	3.2	2
183	Pain management in cryoglobulinaemic syndrome. *Best Practice and Research in Clinical Rheumatology*, **2015**, 29, 77-89	5.3	5
182	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. *Journal of Infectious Diseases*, **2015**, 211, 178-86	7	114
181	Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. *Antiviral Therapy*, **2015**, 20, 449-51	1.6	3
180	OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. *Liver International*, **2015**, 35, 120-9	7.9	4
179	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. *Retrovirology*, **2015**, 12, 33	3.6	36
178	Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. *Aids*, **2015**, 29, 1205-15	3.5	37
177	Reconstruction of the Evolutionary Dynamics of A(H3N2) Influenza Viruses Circulating in Italy from 2004 to 2012. *PLoS ONE*, **2015**, 10, e0137099	3.7	3
176	Reliable timescale inference of HBV genotype A origin and phylodynamics. *Infection, Genetics and Evolution*, **2015**, 32, 361-9	4.5	18
175	Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?. *PLoS ONE*, **2015**, 10, e0123670	3.7	22
174	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. *Retrovirology*, **2014**, 11, 49	3.6	32

173	Fungal endocarditis observed over an 8-year period and a review of the literature. *Mycopathologia*, **2014**, 178, 37-51	2.9	32
172	Validation of the classification criteria for cryoglobulinaemic vasculitis. *Rheumatology*, **2014**, 53, 2209-13	3.9	55
171	Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. *Autoimmunity Reviews*, **2014**, 13, 609-14	13.6	23
170	Phylogeography and phylodynamics of European genotype 3 hepatitis E virus. *Infection, Genetics and Evolution*, **2014**, 25, 138-43	4.5	26
169	OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients. *Antiviral Therapy*, **2014**, 19, 735-45	1.6	5
168	Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. *ClinicoEconomics and Outcomes Research*, **2014**, 6, 409-14	1.7	6
167	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. *Journal of the International AIDS Society*, **2014**, 17, 19769	5.4	3
166	Trends in hospital admissions at a Department for Infectious Diseases in Italy from 1995 to 2011 and implications for health policies. *BMC Public Health*, **2014**, 14, 980	4.1	6
165	Candidaemia observed at a university hospital in Milan (northern Italy) and review of published studies from 2010 to 2014. *Mycopathologia*, **2014**, 178, 227-41	2.9	23
164	Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus. *AIDS Research and Human Retroviruses*, **2014**, 30, 480-3	1.6	
163	Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 67, 493-8	3.1	9
162	Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men. *Infection, Genetics and Evolution*, **2014**, 23, 176-81	4.5	16
161	Durability of lopinavir/ritonavir monotherapy in individuals with viral load 50 copies/ml in an observational setting. *Antiviral Therapy*, **2014**, 19, 319-24	1.6	5
160	Enigmatic origin of hepatitis B virus: an ancient travelling companion or a recent encounter?. *World Journal of Gastroenterology*, **2014**, 20, 7622-34	5.6	56
159	Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. *Infection, Genetics and Evolution*, **2013**, 17, 223-30	4.5	17
158	Profile of infective endocarditis observed from 2003 - 2010 in a single center in Italy. *BMC Infectious Diseases*, **2013**, 13, 545	4	22
157	Novel genetic association of TNF-238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection. *International Journal of Infectious Diseases*, **2013**, 17, e845-50	10.5	14
156	Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. *Journal of Infection*, **2013**, 66, 218-38	18.9	72

155	Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?. *Clinical Infectious Diseases*, **2013**, 57, 480-1	11.6	3
154	Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 1206-7	5.1	5
153	Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2013**, 62, 414-20	3.1	34
152	Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. *Aids*, **2013**, 27, 769-79	3.5	49
151	A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients. *PLoS ONE*, **2013**, 8, e58768	3.7	8
150	Bayesian phylogeography of Crimean-Congo hemorrhagic fever virus in Europe. *PLoS ONE*, **2013**, 8, e79663	3.7	17
149	Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. *PLoS ONE*, **2013**, 8, e80242	3.7	30
148	Reconstruction of the epidemic history of hepatitis B virus genotype D in Albania. *Infection, Genetics and Evolution*, **2012**, 12, 291-8	4.5	28
147	Origin, evolution, and phylogeography of recent epidemic CHIKV strains. *Infection, Genetics and Evolution*, **2012**, 12, 392-8	4.5	31
146	Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals. *AIDS Research and Human Retroviruses*, **2012**, 28, 857-65	1.6	10
145	Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. *AIDS Research and Human Retroviruses*, **2012**, 28, 989-93	1.6	8
144	Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. *BMC Infectious Diseases*, **2012**, 12, 179	4	3
143	Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. *Blood*, **2012**, 119, 6259-67	20.7	75
142	Reconstruction of the evolutionary dynamics of the A(H1N1)pdm09 influenza virus in Italy during the pandemic and post-pandemic phases. *PLoS ONE*, **2012**, 7, e47517	3.7	13
141	Expression of interleukin-15 and interleukin-15R in monocytes of HIV type 1-infected patients with different courses of disease progression. *AIDS Research and Human Retroviruses*, **2012**, 28, 693-701	1.6	9
140	Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of chemokines and RNases. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 5411-6	11.5	34
139	HCV-Negative Mixed Cryoglobulinemia: Facts and Fancies **2012**, 239-243		1
138	Phylogeographic reconstruction of HIV type 1B in Montenegro and the Balkan region. *AIDS Research and Human Retroviruses*, **2012**, 28, 1280-4	1.6	16

137	Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 6132-6	5.9	27
136	Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 460-4	5.1	48
135	Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 2236-42	5.1	16
134	Spatial and temporal dynamics of hepatitis B virus D genotype in Europe and the Mediterranean Basin. *PLoS ONE*, **2012**, 7, e37198	3.7	49
133	HBV/HCV Co-infection and Mixed Cryoglobulinemia **2012**, 227-231		
132	Incidence and Characteristics of Non-Hodgkin Lymphomas in HCV-Positive Patients with Mixed Cryoglobulinemia **2012**, 273-275		
131	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. *Clinical and Experimental Rheumatology*, **2012**, 30, S48-52	2.2	25
130	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. *Aids*, **2011**, 25, 1385-94	3.5	139
129	Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors. *Future Virology*, **2011**, 6, 521-533	2.4	1
128	Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. *Antiviral Therapy*, **2011**, 16, 1103-12	1.6	38
127	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. *Autoimmunity Reviews*, **2011**, 10, 444-54	13.6	165
126	Reconstruction of the evolutionary dynamics of the hepatitis C virus 1b epidemic in Turkey. *Infection, Genetics and Evolution*, **2011**, 11, 863-8	4.5	14
125	Phylogeography and epidemiological history of West Nile virus genotype 1a in Europe and the Mediterranean basin. *Infection, Genetics and Evolution*, **2011**, 11, 646-53	4.5	46
124	Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. *Current HIV Research*, **2011**, 9, 186-93	1.3	20
123	Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results. *Current HIV Research*, **2011**, 9, 625-9	1.3	2
122	Tubercular gluteus abscesses: a return to the early 20th century or a consequence of new, unprecedented behaviors?. *Clinical Infectious Diseases*, **2011**, 52, 1082-3	11.6	4
121	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 192-200	5.1	14
120	Within-host dynamics of the hepatitis C virus quasispecies population in HIV-1/HCV coinfected patients. *PLoS ONE*, **2011**, 6, e16551	3.7	17

119	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. *PLoS ONE*, **2010**, 5, e13540	3.7	73
118	Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy. *PLoS ONE*, **2010**, 5, e15663	3.7	13
117	Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 735-40	5.1	30
116	Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: a pilot study. *AIDS Research and Human Retroviruses*, **2010**, 26, 1207-14	1.6	29
115	Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. *AIDS Patient Care and STDs*, **2010**, 24, 697-703	5.8	15
114	Pandemic influenza vaccine in adult HIV-1-infected patients. *Aids*, **2010**, 24, 2142-3	3.5	18
113	Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2010**, 55, 156-60	3.1	42
112	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. *Aids*, **2010**, 24, 1455-60	3.5	24
111	Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau. *Journal of Infection*, **2010**, 61, 391-8	18.9	9
110	Rapid molecular evolution of human bocavirus revealed by Bayesian coalescent inference. *Infection, Genetics and Evolution*, **2010**, 10, 215-20	4.5	19
109	New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. *Molecules*, **2009**, 14, 1927-37	4.8	5
108	Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. *American Journal of Clinical Pathology*, **2009**, 132, 221-7	1.9	54
107	Bayesian skyline plot inference of the Toscana virus epidemic: a decline in the effective number of infections over the last 30 years. *Infection, Genetics and Evolution*, **2009**, 9, 562-6	4.5	2
106	Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. *Antiviral Therapy*, **2009**, 14, 869-72	1.6	7
105	Different evolutionary rates and epidemic growth of hepatitis B virus genotypes A and D. *Virology*, **2008**, 380, 84-90	3.6	36
104	Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir. *Journal of Clinical Virology*, **2008**, 41, 154-9	14.5	3
103	Subtype assignment and phylogenetic analysis of HIV type 1 strains in patients from Swaziland. *AIDS Research and Human Retroviruses*, **2008**, 24, 323-5	1.6	3
102	Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy. *Clinical Infectious Diseases*, **2008**, 46, 149-50	11.6	6

101	Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of human immunodeficiency virus type 1 unique recombinant forms. *Journal of General Virology*, **2008**, 89, 3119-3125	4.9	13
100	Reversible posterior leukoencephalopathy syndrome in 2 HIV-infected patients receiving antiretroviral therapy. *Clinical Infectious Diseases*, **2008**, 46, e19-22	11.6	17
99	Proven intra and interobserver reliability in the echographic assessments of body fat changes related to HIV associated Adipose Redistribution Syndrome (HARS). *Current HIV Research*, **2008**, 6, 276-8	1.3	2
98	Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. *Aids*, **2008**, 22, 1769-78	3.5	43
97	Description of a "trans-Saharan" strain of human T-lymphotropic virus type 1 in West Africa. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2008**, 47, 269-73	3.1	14
96	Comparability of echographic and tomographic assessments of body fat changes related to the HIV associated adipose redistribution syndrome (HARS) in antiretroviral treated patients. *Ultrasound in Medicine and Biology*, **2008**, 34, 1043-8	3.5	5
95	Risk factors for HIV/AIDS in a low HIV prevalence site of sub-Saharan Africa. *Tropical Medicine and International Health*, **2007**, 12, 1011-7	2.3	11
94	High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. *Virology*, **2007**, 365, 113-24	3.6	56
93	Phylogeny of human T cell lymphotropic virus type 1 in Peru: a high degree of evolutionary relatedness with South African isolates. *AIDS Research and Human Retroviruses*, **2007**, 23, 1146-9	1.6	3
92	Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. *AIDS Patient Care and STDs*, **2007**, 21, 1-3	5.8	16
91	Controversy concerning role of ultrasonographic lipoatrophy assessments in HIV patients. *Aids*, **2006**, 20, 789-90	3.5	8
90	Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. *Aids*, **2006**, 20, 1727-36	3.5	111
89	Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. *American Journal of Gastroenterology*, **2006**, 101, 399-402	0.7	14
88	Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. *Aids*, **2006**, 20, 567-74	3.5	49
87	Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2005**, 40, 238-41	3.1	
86	Increased CD36 expression in vertically human immunodeficiency virus-infected children unrelated to antiretroviral therapy. *Pediatric Infectious Disease Journal*, **2005**, 24, 576-7	3.4	6
85	Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. *Journal of Virology*, **2005**, 79, 9145-56	6.6	31
84	Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol. *AIDS Research and Human Retroviruses*, **2005**, 21, 815-9	1.6	1

83	[13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. *Journal of Antimicrobial Chemotherapy*, **2005**, 55, 84-9	5.1	36
82	Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. *Archives of Internal Medicine*, **2005**, 165, 101-5		137
81	Increased CD36 expression on circulating monocytes during HIV infection. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2005**, 38, 310-3	3.1	11
80	Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. *Journal of Antimicrobial Chemotherapy*, **2004**, 53, 464-8	5.1	16
79	Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma?. *Aids*, **2004**, 18, 1224-6	3.5	6
78	High prevalence of human T-lymphotropic virus type 1 (HTLV-1) in immigrant male-to-female transsexual sex workers with HIV-1 infection. *Journal of Medical Virology*, **2004**, 74, 207-15	19.7	21
77	Establishment of an ex vivo model of monocytes-derived macrophages differentiated from peripheral blood mononuclear cells (PBMCs) from HIV-1 transgenic rats. *Molecular Immunology*, **2004**, 41, 979-84	4.3	13
76	Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. *Journal of Clinical Virology*, **2004**, 29, 27-32	14.5	10
75	Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. *Aids*, **2004**, 18, 211-6	3.5	19
74	Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. *Aids*, **2004**, 18, 574-6	3.5	17
73	Il-7/Il-7 Receptor System Regulation following Il-2 Immunotherapy in HIV-Infected Patients. *Antiviral Therapy*, **2004**, 9, 447-452	1.6	8
72	Immunomodulation Induced by Tucaresol in HIV Infection: Results of a 16 Week Pilot Phase I/II Trial. *Antiviral Therapy*, **2004**, 9, 603-614	1.6	7
71	Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2003**, 34, 58-61	3.1	100
70	Delayed-type hypersensitivity skin testing can predict CD4 count increase in HIV patients with poor immunologic response to HAART. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2003**, 33, 277-8	3.1	2
69	Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting. *Aids*, **2003**, 17 Suppl 1, S155-61	3.5	5
68	Hepatitis B virus genotype distribution in HIV-1 coinfected patients. *Gastroenterology*, **2003**, 125, 1559-60; author reply 1660	13.3	17
67	Pneumocystis carinii pneumonia after the discontinuation of long-term antiretroviral therapy in an HIV-1-infected pregnant woman. *Aids*, **2003**, 17, 940-1	3.5	
66	Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients. *Aids*, **2003**, 17, 257-60	3.5	13

65	Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. *Antiviral Therapy*, **2003**, 8, 347-54	1.6	3
64	Increased Mitochondrial Dna Content in Peripheral Blood Lymphocytes from HIV-Infected Patients with Lipodystrophy. *Antiviral Therapy*, **2003**, 8, 315-321	1.6	46
63	Correlates of Risk of Adipose Tissue Alterations and Their Modifications over Time in HIV-1-Infected Women Treated with Antiretroviral Therapy. *Antiviral Therapy*, **2003**, 8, 347-354	1.6	7
62	Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. *Archives of Internal Medicine*, **2002**, 162, 2621-8		55
61	Maintenance of breast size reduction after mastoplasty and switch to a protease inhibitor-sparing regimen in an HIV-positive woman with highly active antiretroviral therapy-associated massive breast enlargement. *AIDS Patient Care and STDs*, **2002**, 16, 307-11	5.8	11
60	Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. *Clinical Infectious Diseases*, **2002**, 35, 1534-40	11.6	64
59	Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors. *Journal of Infectious Diseases*, **2002**, 186, 143-4	7	13
58	Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. *Journal of Infectious Diseases*, **2002**, 186, 606-16	7	55
57	Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects. *Journal of Antimicrobial Chemotherapy*, **2002**, 49, 427-9	5.1	
56	Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2002**, 29, 21-31	3.1	43
55	Body Habitus Changes and Metabolic Alterations in Protease Inhibitor-Naive HIV-1-Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2002**, 29, 21-31	3.1	86
54	Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. *Blood*, **2001**, 98, 3473-5	2.2	135
53	Resistance to Fas-mediated apoptosis of human T-cell lines expressing human T-lymphotropic virus type-2 (HTLV-2) Tax protein. *Virology*, **2001**, 281, 43-50	3.6	13
52	In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure. *Journal of Clinical Microbiology*, **2001**, 39, 1124-9	9.7	11
51	Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. *Journal of Clinical Microbiology*, **2001**, 39, 357-61	9.7	61
50	Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. *Aids*, **2001**, 15, 965-74	3.5	37
49	Virological Response in Multidrug-Experienced HIV-1-Infected Subjects Failing Highly Active Combination Regimens after Shifting from Lamivudine to Didanosine. *Antiviral Therapy*, **2001**, 6, 41-46	1.6	4
48	Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2000**, 24, 232-40	3.1	22

47	Prevalence of Multiple Dideoxynucleoside Analogue Resistance (MddNR) in a Multicenter Cohort of HIV-1Infected Italian Patients With Virologic Failure. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2000**, 24, 232-240	3.1	25
46	Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. *Aids*, **2000**, 14, 1101-10	3.5	9
45	Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 1328-32	5.9	88
44	Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. *Journal of Virology*, **2000**, 74, 9328-32	6.6	28
43	Body habitus alterations in HIV-infected women treated with combined antiretroviral therapy. *AIDS Patient Care and STDs*, **2000**, 14, 595-601	5.8	8
42	Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations in Pol Reverse Transcriptase and Protease Region: Outcome after Treatment in Recently Infected Individuals. *Antiviral Therapy*, **2000**, 5, 7-14	1.6	21
41	Persisting HIV-1 Replication Triggered by Acute Hepatitis a Virus Infection. *Antiviral Therapy*, **2000**, 5, 15-17	1.6	10
40	Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. *Journal of Infectious Diseases*, **1999**, 180, 285-9	7	26
39	Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation. *AIDS Research and Human Retroviruses*, **1999**, 15, 861-7	1.6	5
38	Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering. *Clinical Immunology*, **1999**, 92, 276-84	9	9
37	CD4 cell counts at the third month of HAART may predict clinical failure. *Aids*, **1999**, 13, 1669-76	3.5	43
36	Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. *Aids* , **1999**, 13, 465-71	3.5	234
35	Low CD4 counts rather than superantigenic-like effects account for differences in expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. *British Journal of Haematology*, **1998**, 102, 1187-96	4.5	10
34	Lack of in vitro anti-gp160 antibody production is a correlate of nonprogression among HIV type 1-infected individuals. *AIDS Research and Human Retroviruses*, **1998**, 14, 1341-3	1.6	3
33	Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. *Aids*, **1998**, 12, 1631-7	3.5	110
32	Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy. *Journal of Virology*, **1998**, 72, 7664-8	6.6	14
31	High prevalence of false-negative anti-HTLV type I/II enzyme-linked immunosorbent assay results in HIV type 1-positive patients. *AIDS Research and Human Retroviruses*, **1997**, 13, 1141-6	1.6	18
30	Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. *Journal of Infectious Diseases*, **1997**, 176, 1209-14	7	43

29	Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. *Aids*, **1997**, 11, F67-71	3.5	91
28	Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. *Science*, **1997**, 278, 1969-70; author reply 1972-3	33.3	77
27	Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors. *Clinical Immunology and Immunopathology*, **1997**, 85, 320-3		4
26	Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. *Pediatric Infectious Disease Journal*, **1997**, 16, 205-11	3.4	17
25	Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. *Aids*, **1996**, 10, 23-30	3.5	38
24	Soluble HIV suppressive factors: more than one Holy Grail?. *Trends in Immunology*, **1996**, 17, 297-8		12
23	The role of human herpesvirus 8 and Epstein-Barr virus in the pathogenesis of giant lymph node hyperplasia (Castleman's disease). *Clinical Infectious Diseases*, **1996**, 22, 1120-1	11.6	57
22	Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. *AIDS Research and Human Retroviruses*, **1996**, 12, 1053-61	1.6	83
21	HIV type 1 phenotype correlates with the stage of infection in vertically infected children. *AIDS Research and Human Retroviruses*, **1996**, 12, 1247-53	1.6	29
20	HTLV infection in ELISA-negative blood donors. *AIDS Research and Human Retroviruses*, **1996**, 12, 737-40	1.6	11
19	Frequent detection of antibodies against HTLV antigens in patients with AIDS-related non-Hodgkin lymphoma. *AIDS Research and Human Retroviruses*, **1995**, 11, 823-7	1.6	12
18	Serum 2'-5'-oligoadenylate synthetase levels and clinical response to interferon-beta therapy in women with genital human papillomavirus infection. *Journal of Infectious Diseases*, **1994**, 169, 1112-5	7	12
17	The syndrome of acquired glucocorticoid resistance in HIV infection. *Baillierels Clinical Endocrinology and Metabolism*, **1994**, 8, 777-87		27
16	Hepatitis C virus and mixed cryoglobulinaemias. *Lancet, The*, **1992**, 339, 989	40	36
15	Cryoglobulinaemia and serological markers of hepatitis viruses. *Lancet, The*, **1991**, 338, 758-9	40	21
14	Clinical and immunological aspects of HIV infection in drug addicts. *Clinical Immunology and Immunopathology*, **1989**, 50, S166-76		17
13	Thymostimulin treatment in AIDS-related complex. *Clinical Immunology and Immunopathology*, **1988** , 47, 253-61		7
12	Retrobulbar optic neuritis in a patient with acute type B hepatitis. *Journal of the Neurological Sciences*, **1986**, 72, 195-200	3.2	8

11	The cryoglobulinemic syndrome. *Research in Clinic and Laboratory*, **1986**, 16, 269-74		3
10	Pulmonary candidiasis in a heroin addict: some remarks on its aetiology and pathogenesis. *Addiction*, **1985**, 80, 103-4	4.6	5
9	Specific IgE response in dracunculiasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **1985**, 79, 283	2	0
8	Structural skull defects in type IV Ehlers-Danlos syndrome. *British Journal of Dermatology*, **1984**, 110, 122-4	4	4
7	Myasthenia gravis with a monoclonal gammopathy--report of a case. *Journal of the Neurological Sciences*, **1980**, 45, 103-8	3.2	13
6	Early Phylogenetic Estimate Of The Effective Reproduction Number Of 2019-nCoV		8
5	GENOMIC CHARACTERISATION AND PHYLOGENETIC ANALYSIS OF SARS-COV-2 IN ITALY		8
4	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOVID19 Web-Based Survey (Preprint)		1
3	Molecular tracing of SARS-CoV-2 in Italy in the first three months of the epidemic		1
2	The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity		53
1	The Milano Sforza Registers		1